IV Antibiotic Dosing for Community-Acquired Pneumonia
For hospitalized adults with non-severe CAP, use combination therapy with a β-lactam plus macrolide: ceftriaxone 1-2 g IV daily (or cefotaxime 1-2 g IV every 8 hours, or ampicillin-sulbactam 1.5-3 g IV every 6 hours) PLUS azithromycin 500 mg IV/PO daily, OR alternatively use monotherapy with levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily 1.
Dosing Algorithm by Severity
Non-Severe CAP (Hospitalized, Non-ICU)
First-line options (equal preference):
β-lactam + Macrolide combination:
- Ceftriaxone 1-2 g IV every 24 hours, OR
- Cefotaxime 1-2 g IV every 8 hours, OR
- Ampicillin-sulbactam 1.5-3 g IV every 6 hours, OR
- Ceftaroline 600 mg IV every 12 hours
PLUS
- Azithromycin 500 mg IV/PO daily, OR
- Clarithromycin 500 mg IV/PO twice daily
Respiratory fluoroquinolone monotherapy:
- Levofloxacin 750 mg IV daily, OR
- Moxifloxacin 400 mg IV daily
Alternative (if contraindications to both macrolides and fluoroquinolones):
- β-lactam (doses as above) + Doxycycline 100 mg IV/PO twice daily 1
Severe CAP (ICU-level)
Use β-lactam + macrolide OR β-lactam + respiratory fluoroquinolone (same agents and doses as above, but avoid fluoroquinolone monotherapy) 1.
Key Clinical Considerations
Duration: The 2025 ATS guidelines now recommend minimum 3 days (less than 5 days total) for non-severe CAP once clinical stability is reached, rather than the traditional ≥5 days. For severe CAP, continue 5 or more days 2, 3.
IV vs. Oral: Levofloxacin has 100% oral bioavailability and is bioequivalent to IV formulation, allowing seamless switching between routes 4. Recent evidence suggests oral antibiotics may be safe for selected moderate-to-severe CAP patients, though IV-treated patients had 2.6 days longer hospital stays without mortality differences 5.
Antibiotic Class Rotation: If the patient had recent exposure to one antibiotic class, switch to a different class due to increased resistance risk 1.
Common Pitfalls to Avoid
- Don't use β-lactam monotherapy in hospitalized CAP—atypical pathogen coverage is essential
- Don't use fluoroquinolone monotherapy in severe CAP—combination therapy is superior
- Don't continue antibiotics beyond clinical stability in non-severe cases—3-5 days is sufficient 2, 3
- Don't forget MRSA/Pseudomonas risk factors—these require different coverage (vancomycin or linezolid for MRSA; anti-pseudomonal β-lactams for Pseudomonas) 1
The evidence strongly supports β-lactam/macrolide combination as equivalent or superior to fluoroquinolone monotherapy, with systematic reviews showing lower mortality with combination therapy compared to β-lactam alone 1. The high-dose, short-course levofloxacin (750 mg) maximizes concentration-dependent killing and reduces resistance development 4.